Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Martin

Showing results (231-240 of 241) with videos related to

Pageof 25
Sort By:
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Science (New York, N.Y.)|January 29, 2026
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapyJunedh M Amrute, In-Hyuk Jung, Tracy Yamawaki, et al.
Journal of Medicinal Chemistry|September 27, 2021
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPsJeffrey W Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry|January 27, 2025
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion MutationsWilliam McCoull, Clare Thomson, Erin Braybrooke, et al.
Nature Cancer|June 5, 2023
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistanceThijs J Hagenbeek, Jason R Zbieg, Marc Hafner, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 27, 2019
Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock InitiativeMir B Basir, Navin K Kapur, Kirit Patel, et al.
Journal of Medicinal Chemistry|January 9, 2014
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymeraseRobert G Gentles, Min Ding, John A Bender, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Nature Communications|June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer modelThijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.
Pageof 25

Showing results (231-240 of 241) with videos related to

Sort By:
Pageof 25
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Science (New York, N.Y.)|January 29, 2026
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapyJunedh M Amrute, In-Hyuk Jung, Tracy Yamawaki, et al.
Journal of Medicinal Chemistry|September 27, 2021
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPsJeffrey W Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry|January 27, 2025
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion MutationsWilliam McCoull, Clare Thomson, Erin Braybrooke, et al.
Nature Cancer|June 5, 2023
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistanceThijs J Hagenbeek, Jason R Zbieg, Marc Hafner, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 27, 2019
Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock InitiativeMir B Basir, Navin K Kapur, Kirit Patel, et al.
Journal of Medicinal Chemistry|January 9, 2014
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymeraseRobert G Gentles, Min Ding, John A Bender, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Nature Communications|June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer modelThijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.
Pageof 25